We are live on ! Find out more
PCSA icon

Processa Pharmaceuticals
PCSA

9 hedge funds and large institutions have $251K invested in Processa Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more capital inflows, than outflows

Capital inflows: $283K | Capital outflows: $255K

0.87% less ownership

Funds ownership: 4.59% → 3.72% (-0.87%)

50% less funds holding

Funds holding: 18 → 9 (-9)

75% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 12

Holders
9
Holders Change
-9
Holders Change %
-50%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
–
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$154K
2
Two Sigma Investments
Two Sigma Investments
New York
+$73.4K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$40.2K
4
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$14.1K
5
UBS Group
UBS Group
Switzerland
+$555

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$106K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$40.8K
3
Spinnaker Trust
Spinnaker Trust
Maine
-$25.7K
4
Coastal Bridge Advisors
Coastal Bridge Advisors
Connecticut
-$21.7K
5
Renaissance Technologies
Renaissance Technologies
New York
-$19K

PCSA Hedge Fund Activity: Q1 2024 in Review

9 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q1 2024, worth a combined $251K — down 33% from $376K a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of PCSA and 3 opened new positions — a net loss of 9 holders — while 0 trimmed existing stakes and 5 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $154K. The largest seller was Citadel Advisors, exiting entirely with an estimated $106K sold.

  • 9 institutional investors held Processa Pharmaceuticals (PCSA) as of Q1 2024, down from 18 in Q4 2023.
  • Funds reported $251K of Processa Pharmaceuticals stock for Q1 2024, down 33% quarter-over-quarter.
  • 3 funds opened new Processa Pharmaceuticals positions in Q1 2024 and 12 closed out, a net change of -9 holders.
  • The largest Processa Pharmaceuticals buyer in Q1 2024 was Sabby Management, an estimated $154K added.
  • The largest Processa Pharmaceuticals seller in Q1 2024 was Citadel Advisors, an estimated $106K sold.

Based on aggregated 13F filings for Q1 2024.